StockNews.AI
SLNO
StockNews.AI
127 days

Soleno Therapeutics Announces VYKAT(TM) XR Launch

1. VYKAT XR, Soleno's treatment for PWS, is commercially available. 2. First prescriptions for VYKAT XR delivered after FDA approval on March 26, 2025. 3. Strong interest reported from healthcare providers and caregivers for VYKAT XR. 4. Soleno established a support program to assist with treatment access. 5. PWS affects one in 15,000 live births, indicating a niche market.

8m saved
Insight
Article

FAQ

Why Bullish?

The successful launch of VYKAT XR, addressing a significant health issue, likely enhances SLNO's stock appeal. Similar launches in the past, such as those seen in rare disease treatments by companies like Vertex Pharmaceuticals, often lead to stock price increases due to new revenue streams.

How important is it?

The article addresses the first commercial availability of a unique treatment for a rare condition, highlighting economic and therapeutic potential, which directly relates to SLNO's stock value.

Why Long Term?

The introduction of VYKAT XR opens long-term revenue potential as more prescriptions are filled and awareness grows in the PWS community. Historical cases show long-term benefits for companies with established treatments for rare diseases.

Related Companies

VRTXAVEOSPPI
First prescriptions delivered to individuals with PWS April 14, 2025 07:00 ET  | Source: Soleno Therapeutics REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the U.S. commercial availability of VYKAT™ XR (diazoxide choline) extended-release tablets, the company’s treatment for hyperphagia in patients four years of age and older with Prader-Willi syndrome (PWS), which was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025. Prescriptions of VYKAT XR have now been delivered to the first individuals living with PWS who have been prescribed the medication. “We are extremely pleased to begin delivering VYKAT XR, the only FDA-approved treatment for hyperphagia, to individuals living with PWS. Hyperphagia, the hallmark condition of PWS, is the leading cause of mortality in the PWS population and creates a significant burden for caregivers,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics. “Since FDA approval, we have seen strong interest in VYKAT XR. Our team is fully prepared to meet demand and is well-positioned to execute a successful commercial launch of this first-to-market treatment. These first shipments mark an important step in our efforts to deliver this new treatment to the PWS community and are an exciting milestone reflecting our dedication to ensuring timely access to treatment.” Soleno has established a comprehensive support program, Soleno ONE™, to assist patients, caregivers and healthcare providers with access to VYKAT XR. For more information, visit www.VykatXR.com or contact Soleno ONE toll-free at 1-833-SOLENO-1 (1-833-765-3661). Healthcare providers who want to write prescriptions can visit www.VykatXRHCP.com to complete the Start Form and initiate the process for access to treatment. About PWSPrader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15. The Prader-Willi Syndrome Association USA estimates that PWS occurs in one in every 15,000 live births. The defining symptom of PWS is hyperphagia, a chronic and life-threatening condition characterized by an intense persistent sensation of hunger accompanied by food preoccupations, an extreme drive to consume food, food-related behavior problems, and a lack of normal satiety, which can severely diminish the quality of life for individuals with PWS and their families. Hyperphagia can lead to significant mortality (e.g., stomach rupture, choking, accidental death due to food seeking behavior) and longer term, co-morbidities such as diabetes, obesity, and cardiovascular disease. INDICATIONVYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS). IMPORTANT SAFETY INFORMATION ContraindicationsUse of VYKAT XR is contraindicated in patients who have a known hypersensitivity to diazoxide, other components of VYKAT XR, or to thiazides. Warnings and Precautions HyperglycemiaHyperglycemia, including diabetic ketoacidosis, has been reported. Before initiating VYKAT XR, test fasting plasma glucose (FPG) and HbA1c; optimize blood glucose in patients who have hyperglycemia. During treatment, regularly monitor fasting glucose (FPG or fasting blood glucose) and HbA1c. Monitor fasting glucose more frequently during the first few weeks of treatment in patients with risk factors for hyperglycemia. Risk of Fluid OverloadEdema, including severe reactions associated with fluid overload, has been reported. Monitor for signs or symptoms of edema or fluid overload. VYKAT XR has not been studied in patients with compromised cardiac reserve and should be used with caution in these patients. Adverse ReactionsThe most common adverse reactions (incidence ≥10% and at least 2% greater than placebo) included hypertrichosis, edema, hyperglycemia, and rash. Please see the full Prescribing Information, including Medication Guide. About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s first commercial product, VYKAT XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome. For more information, please visit www.soleno.life. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the timing of commercialization of VYKAT XR for the treatment of hyperphagia in individuals with PWS, the potential market opportunity for VYKAT XR and the ability of VYKAT XR to address the unmet needs of the PWS community. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including those described in the company's prior press releases and in the periodic reports it files with the SEC. The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Corporate Contact:Brian RitchieLifeSci Advisors, LLC212-915-2578 Media Contact:media@soleno.life

Related News